Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same|
|Abstract:||Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.|
|Inventor(s):||Jeffs; Roger Andrew (Chapel Hill, NC), Zaccardelli; David (Cary, NC)|
|Assignee:||United Therapeutics Corporation (Silver Spring, MD)|
1. A method of reducing occurrence of a bacterial infection in a human suffering from pulmonary arterial hypertension, who is undergoing treatment for said pulmonary
hypertension, associated with occurrence of a bacterial infection comprising diluting a starting solution of an active pharmaceutical ingredient other than epoprostenol with a buffer comprising glycine and having a pH of greater than 10 to provide a
final solution with a pH of greater than 10 and an amount of the active pharmaceutical ingredient other than epoprostenol effective for treating pulmonary arterial hypertension, and administering said final solution to the human subject in need thereof.
2. The method of claim 1, wherein the buffer further comprises sodium hydroxide.
3. The method of claim 1, wherein the buffer has a pH between 10 and 12.
4. The method of claim 3, wherein the buffer has a pH between 10.2 and 10.8.
5. The method of claim 1, wherein the final solution is administered at a concentration between about 0.001 mg/mL to about 1 mg/mL.
6. The method of claim 1, wherein the final solution is administered at a concentration between about 0.004 mg/mL to about 0.13 mg/mL.
7. The method of claim 1, wherein the administering is by injection.
8. The method of claim 7, wherein the injection is intravenous injection.
9. The method according to claim 1, wherein the administration reduces the growth of gram negative bacteria.
10. The method of claim 4, wherein the final solution is administered intravenously.
11. The method of claim 1, wherein the buffer is a 50 mL solution of 94 mg of glycine, 73.3 mg of sodium chloride, and sodium hydroxide.
12. The method of claim 11, wherein the administering is by injection.
13. The method of claim 12, wherein the injection is intravenous injection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.